DESTINY-Breast03 Phase 3 Study Results
Best Percent Change
From Baseline
Change in Tumor Size From Baseline
60'
622
40
20
0
-20
-40
-60°
-80
-100
Best Percent Change
From Baseline
-60
-80
® ¥ ° ॰ ༠ Ş ྣ ཚྭ
-20
-40
-100
HR+/HER2-
TNBCa
HER3 Expression
High
Low
Patients (n=106)
60
HER2+a
Patients (n=51)
-40
-60
82202788
-100
Daiichi-Sankyo
Patients (n=13)
HER3-DXd induced a clinically meaningful decrease in tumor size by BICR in most patients across BC subtypes b
a Patients with TNBC and HER2+ were all HER3-high.
b Best percentage change from baseline in sum of diameters based on BICR for all target lesions identified is represented by patient. If any lesion measurement is missing at a post-baseline tumor assessment visit,
that visit is not taken into consideration for best percent change from baseline in sum of diameters.
ASCO 2022 #1002 Oral
89View entire presentation